Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
164.83
+4.00 (2.49%)
Dec 20, 2024, 4:00 PM EST - Market closed
Krystal Biotech Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Krystal Biotech stock have an average target of 206.67, with a low estimate of 175 and a high estimate of 221. The average target predicts an increase of 25.38% from the current stock price of 164.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KRYS stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 7 | 6 | 6 | 5 | 4 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 9 | 9 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $212 | Strong Buy | Maintains | $212 | +28.62% | Dec 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $221 | Strong Buy | Reiterates | $221 | +34.08% | Dec 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $221 | Strong Buy | Reiterates | $221 | +34.08% | Dec 13, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $212 | Strong Buy | Maintains | $212 | +28.62% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $221 | Strong Buy | Reiterates | $221 | +34.08% | Dec 10, 2024 |
Financial Forecast
Revenue This Year
296.92M
from 50.70M
Increased by 485.65%
Revenue Next Year
471.03M
from 296.92M
Increased by 58.64%
EPS This Year
2.81
from 0.39
Increased by 619.88%
EPS Next Year
5.98
from 2.81
Increased by 113.14%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 311.2M | 566.2M | 971.4M | |||
| Avg | 296.9M | 471.0M | 667.8M | |||
| Low | 274.4M | 377.3M | 499.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 513.9% | 90.7% | 106.2% | |||
| Avg | 485.7% | 58.6% | 41.8% | |||
| Low | 441.2% | 27.1% | 5.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 3.74 | 8.43 | 16.31 | |
| Avg | 2.81 | 5.98 | 9.12 | |
| Low | 1.88 | 2.95 | 4.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 858.5% | 200.3% | 172.5% | |
| Avg | 619.9% | 113.1% | 52.4% | |
| Low | 382.5% | 5.1% | -19.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.